ZYMETX INC
10KSB, EX-27.1, 2000-10-13
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: ZYMETX INC, 10KSB, EX-10.23, 2000-10-13
Next: GLOBEFLEX CAPITAL L P, 13F-HR, 2000-10-13



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          JUN-30-2000
<PERIOD-START>                             JUL-01-1999
<PERIOD-END>                               JUN-30-2000
<CASH>                                       1,357,509
<SECURITIES>                                 2,458,801
<RECEIVABLES>                                   28,912
<ALLOWANCES>                                    20,111
<INVENTORY>                                  2,528,664
<CURRENT-ASSETS>                             5,881,693
<PP&E>                                       1,039,426
<DEPRECIATION>                                 454,963
<TOTAL-ASSETS>                               7,151,597
<CURRENT-LIABILITIES>                        1,265,784
<BONDS>                                        413,918
                                0
                                          0
<COMMON>                                         6,837
<OTHER-SE>                                   5,465,058
<TOTAL-LIABILITY-AND-EQUITY>                 7,151,597
<SALES>                                      1,224,820
<TOTAL-REVENUES>                             1,224,820
<CGS>                                          643,935
<TOTAL-COSTS>                                7,550,888
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                               913,861
<INTEREST-EXPENSE>                              36,173
<INCOME-PRETAX>                            (6,778,841)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (6,778,841)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (6,778,841)
<EPS-BASIC>                                     (1.00)
<EPS-DILUTED>                                   (1.00)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission